Denosumab Versus Oral Bisphosphonate (Alendronate) for Osteoporosis in Long-term Glucocorticoid Users: an Open Randomized Controlled Trial

Trial Profile

Denosumab Versus Oral Bisphosphonate (Alendronate) for Osteoporosis in Long-term Glucocorticoid Users: an Open Randomized Controlled Trial

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Denosumab (Primary) ; Alendronic acid
  • Indications Osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Apr 2017 Planned End Date changed from 1 Dec 2019 to 1 Feb 2020.
    • 16 Apr 2017 Planned primary completion date changed from 1 Apr 2019 to 1 Jun 2019.
    • 03 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top